No description available.

A depressão, também conhecida como distúrbio depressivo maior, é uma doença extremamente séria caracterizada por distúrbios afetivos que apresenta sintomas como tristeza, pessimismo, baixa autoestima, alterações nas funções vegetativas como sono e apetite e cognitivas como concentração, memória e atenção. A depressão afeta hoje cerca de 300 milhões de pessoas sendo essa a doença mais incapacitante do mundo, segundo dados da Organização Mundial da Saúde. O receptor humano 5-HT2a tem sido associado a inúmeras condições neurológicas e moléculas ligantes seletivas a esse receptor podem apresentar potencial terapêutico no tratamento de distúrbios de comportamento, tais como a depressão. Com o propósito de contribuir para o planejamento de novos fármacos mais eficazes no tratamento da depressão realizou-se um estudo de QSAR (do inglês Quantitative structure-activity Relationship) com um conjunto de 106 compostos arilpiperazínicos utilizando os métodos de Mínimos Quadrados Parciais (PLS) e Redes Neurais Artificias (ANN). O modelo de PLS foi obtido com 76 compostos no conjunto de treinamento e 11 compostos no conjunto teste (r2 = 0,749 e q2 = 0,696). Os testes de validação leave-N-out, randomização e detecção de outliers confirmaram a robustez e estabilidade dos modelos e demonstraram que os mesmos não foram gerados através de correlações ao acaso. O modelos de Redes Neurais Artificiais de Perceptron de Multicamadas (MLP-ANN) foi gerado utilizando funções de transferência tansig-tansig. O treinamento das redes demonstrou que o melhor modelo apresentava arquitetura 7-10-1. Tal modelo apresentou valores de erro quadrático médio (EQM) igual a 0,00964, desvio médio absoluto (DMA) igual a 0,0775 e r2treinamento, r2validação e r2teste iguais a 0,794, 0,795 e 0,788, respectivamente. Os descritores dos modelos matemáticos gerados mostraram concordância com as propriedades moleculares dos compostos e os valores de atividade biológica preditos pelos modelos de PLS e ANN demonstraram que a interação dos descritores é satisfatoriamente relacionada tanto por aproximações lineares quanto não-lineares. / Depression, major depressive disorder or clinical depression, is a serious mood disorder characterized by severe symptoms like emotional suffering and feeling miserable that affects vegetative functions as sleeping and eating and cognitive functions like concentration, memory and attention. The world mental health estimates that depression affects more than 300 million people worldwide and is the leading cause of world disability. The human receptor 5-HT2a has been associated to many neurological dysfunctions. Molecules that selectively bind to this receptor present the potential to be used as an effective treatment of mental health disorders, such as depression. Our primary aim in this work is to contribute to the development of new drugs for the treatment of depression. Quantitative Structure-Activity Relationships (QSAR) studies with a series of 106 arylpiperazines that interact with the neuroreceptor 5-HT2a were conducted employing the methods Partial Least Squares (PLS) and Artificial Neural Networks (ANN). The PLS model was obtained with a training set of 76 compounds and a 19 compounds test set (r² = 0. 749, q² = 0.696). Leave-N-out analysis, biological activity randomization and outliers detection confirmed the robustness and stability of the models and showed that they were not obtained by chance correlations. Predictive models were also generated by Multilayer Perceptron Artificial Neural Network (MLP-ANN) trained with tansig-tansig transfer functions showed that the best results were obtained for a 7-10-1 architecture (r²training = 0. 794, r²validation = 0.795 and r²test = 0.788). The descriptors used to construct the predictive models showed good agreement with the arylpiperazines molecular properties, and the biological activity predicted by the PLS and ANN methods suggested that the descriptor interactions can be described by a linear or a nonlinear approach as well.

A depressão, também conhecida como distúrbio depressivo maior, é uma doença extremamente séria caracterizada por distúrbios afetivos que apresenta sintomas como tristeza, pessimismo, baixa autoestima, alterações nas funções vegetativas como sono e apetite e cognitivas como concentração, memória e atenção. A depressão afeta hoje cerca de 300 milhões de pessoas sendo essa a doença mais incapacitante do mundo, segundo dados da Organização Mundial da Saúde. O receptor humano 5-HT2a tem sido associado a inúmeras condições neurológicas e moléculas ligantes seletivas a esse receptor podem apresentar potencial terapêutico no tratamento de distúrbios de comportamento, tais como a depressão. Com o propósito de contribuir para o planejamento de novos fármacos mais eficazes no tratamento da depressão realizou-se um estudo de QSAR (do inglês Quantitative structure-activity Relationship) com um conjunto de 106 compostos arilpiperazínicos utilizando os métodos de Mínimos Quadrados Parciais (PLS) e Redes Neurais Artificias (ANN). O modelo de PLS foi obtido com 76 compostos no conjunto de treinamento e 11 compostos no conjunto teste (r2 = 0,749 e q2 = 0,696). Os testes de validação leave-N-out, randomização e detecção de outliers confirmaram a robustez e estabilidade dos modelos e demonstraram que os mesmos não foram gerados através de correlações ao acaso. O modelos de Redes Neurais Artificiais de Perceptron de Multicamadas (MLP-ANN) foi gerado utilizando funções de transferência tansig-tansig. O treinamento das redes demonstrou que o melhor modelo apresentava arquitetura 7-10-1. Tal modelo apresentou valores de erro quadrático médio (EQM) igual a 0,00964, desvio médio absoluto (DMA) igual a 0,0775 e r2treinamento, r2validação e r2teste iguais a 0,794, 0,795 e 0,788, respectivamente. Os descritores dos modelos matemáticos gerados mostraram concordância com as propriedades moleculares dos compostos e os valores de atividade biológica preditos pelos modelos de PLS e ANN demonstraram que a interação dos descritores é satisfatoriamente relacionada tanto por aproximações lineares quanto não-lineares. / Depression, major depressive disorder or clinical depression, is a serious mood disorder characterized by severe symptoms like emotional suffering and feeling miserable that affects vegetative functions as sleeping and eating and cognitive functions like concentration, memory and attention. The world mental health estimates that depression affects more than 300 million people worldwide and is the leading cause of world disability. The human receptor 5-HT2a has been associated to many neurological dysfunctions. Molecules that selectively bind to this receptor present the potential to be used as an effective treatment of mental health disorders, such as depression. Our primary aim in this work is to contribute to the development of new drugs for the treatment of depression. Quantitative Structure-Activity Relationships (QSAR) studies with a series of 106 arylpiperazines that interact with the neuroreceptor 5-HT2a were conducted employing the methods Partial Least Squares (PLS) and Artificial Neural Networks (ANN). The PLS model was obtained with a training set of 76 compounds and a 19 compounds test set (r² = 0. 749, q² = 0.696). Leave-N-out analysis, biological activity randomization and outliers detection confirmed the robustness and stability of the models and showed that they were not obtained by chance correlations. Predictive models were also generated by Multilayer Perceptron Artificial Neural Network (MLP-ANN) trained with tansig-tansig transfer functions showed that the best results were obtained for a 7-10-1 architecture (r²training = 0. 794, r²validation = 0.795 and r²test = 0.788). The descriptors used to construct the predictive models showed good agreement with the arylpiperazines molecular properties, and the biological activity predicted by the PLS and ANN methods suggested that the descriptor interactions can be described by a linear or a nonlinear approach as well.

Previous research indicates that serotonin (5-HT) enhances the acquisition of stress-induced changes in behavior; although it is unclear which serotonin receptors mediate this enhancement. 5-HT2 receptors are potential candidates because activation at these receptors is associated with increased fear and anxiety. In this study we investigated whether pharmacological treatments targeting 5-HT2A and 5-HT2C receptors modulated the acquisition and expression of conditioned defeat. Conditioned defeat is a social defeat model in Syrian hamsters (Mesocricetus auratus) that is characterized by increased submissive and defensive behavior and a loss of territorial aggression following social defeat. In experiment 1, we injected the 5-HT2C receptor agonist mCPP (0.3, 1.0, or 3.0 mg/kg) or vehicle prior to social defeat and tested subjects for conditioned defeat behavior in a social interaction test 24 hours later. In experiment 2, subjects received a social defeat, and 24 hours later we injected mCPP (0.3, 1.0, or 3.0 mg/kg) or vehicle prior to a social interaction test. We found that injection of mCPP increased the expression, but not acquisition, of conditioned defeat. In experiment 3, we injected the 5-HT2A receptor antagonist MDL 11,939 (0.5 or 2.0 mg/kg) or vehicle prior to a social defeat and tested subjects for conditioned defeat behavior. In experiment 4, subjects received a social defeat, and 24 hours later we injected MDL 11,939 (0.5 or 2.0 mg/kg) or vehicle prior to a social interaction test. We found that injection of MDL 11,939 significantly decreased the acquisition, but not expression, of conditioned defeat. These data suggest that pharmacological activation of 5-HT2C receptors enhances the expression of conditioned defeat, while pharmacological blockade of 5-HT2A receptors impairs the acquisition of conditioned defeat. These data extend other studies indicating that 5-HT signaling at 5-HT2A receptors facilitate memories for aversive events and 5-HT signaling at 5-HT2C receptors enhance stress-induced anxiety.

Thesis (Ph.D.)--Virginia Commonwealth University, 2009. / Prepared for: Dept. of Medicinal Chemistry. Title from title-page of electronic thesis. Bibliography: leaves 141-177.

Thesis (Ph. D.)--Case Western Reserve University, 2006. / [School of Medicine] Department of Neurosciences. Includes bibliographical references. Available online via OhioLINK's ETD Center.

Major depression disorder is increasing globally, causing great personal suffering and economic burdens to society. Current antidepressant medications are not sufficiently able to treat all cases of depression and are often associated with troubling side effects. There is a great need for the development of novel treatments, and classic psychedelic drugs are currently being investigated with new interest. The legal status has hindered research, but promising results from pioneering studies on the antidepressant effect of psilocybin have recently given psilocybin breakthrough therapy status, allowing further research to occur more freely. This systematic review aims to investigate the literature available on psilocybin’s effect on major depressive disorder. Five studies were selected according to set inclusion and exclusion criteria. Results are suggesting that psilocybin combined with psychological support is a fast-acting antidepressant agent, able to produce a sustained decrease in symptoms of depression with minimal side effects. However, current studies come with several limitations and further research is needed before the antidepressant effect of psilocybin can be stated as a fact.

No description available.

No description available.

Les astrocytes joueraient un rôle central dans la physiopathologie des troubles anxio-dépressifs et dans l’activité thérapeutique des antidépresseurs. En effet, différentes études in vitro suggèrent que les inhibiteurs sélectifs de recapture de la sérotonine (ISRS) stimulent la synthèse de substances neuroactives par ces cellules gliales nécessaires à la prolifération, la maturation et la survie neuronale mais également au maintien de la plasticité synaptique. Le Brain-derived neurotrophic factor (BDNF) fait partie de ces substances mais son origine, notamment astrocytaire, doit encore être démontrée dans les systèmes intégrés tel que l’animal vivant. A partir de ce constat, dans une première partie de ce travail de thèse, nous avons donc voulu préciser si les astrocytes constituent une source cellulaire participant à la synthèse et/ou à la libération de BDNF en réponse à l’administration prolongée d’un ISRS, la fluoxétine d’une part chez des souris naïves et d’autre part chez des souris exposées à la corticostérone pendant plusieurs semaines (modèle « CORT »). Pour cela, nous avons utilisé une stratégie de transfection virale induisant la surexpression de BDNF spécifiquement dans les astrocytes de l'hippocampe. Nos résultats mettent en lumière que cette surexpression provoque des effets de types anxiolytiques-antidépresseurs dépendant de la neurogenèse hippocampique chez des souris naïves soumises au test d’hypophagie induite par la nouveauté mais pas dans le modèle CORT. Nous avons également mis en évidence que le BDNF pouvait agir en retour sur les cellules qui l’ont libéré pour renforcer le réseau astrocytaire (mécanisme autocrine) mais également sur les neurones sérotoninergiques pré-synaptiques (mécanisme paracrine) pour exercer un frein sur la libération de sérotonine dans l’hippocampe. Différents arguments de la littérature suggèrent d’ailleurs que ce dernier mécanisme pourrait être favorable à l’activité anxiolytique de la fluoxétine tel que nous l’avons observé dans ce travail. Sachant que les astrocytes expriment à leur surface, une grande variété de récepteurs sérotoninergiques, nous nous sommes ensuite intéressé à la possibilité que le sous-type de récepteur 5-HT2A pourrait être un élément clé dans la synthèse et/ou la libération de BDNF et de ce fait moduler la réponse au stress et celle à la fluoxétine. Lors de cette seconde étude nous avons appliqué une approche génétique utilisant des souris mutées, privées de manière constitutive du récepteur 5-HT2A (5-HT2A-/-). A l’opposé de la surexpression de BDNF dans les astrocytes, nous avons montré que les souris 5-HT2A-/- sont plus sensibles au stress, modélisé par l’exposition chronique à la corticostérone, et semblent résistantes à la fluoxétine comparées aux souris 5-HT2A+/+. Afin de préciser le mécanisme pouvant rendre compte de ces observations, nous avons mis en évidence que l’inactivation du récepteur 5-HT2A s’accompagne d’une hypersensibilité du frein inhibiteur exercé par les autorécepteurs 5-HT1A somatodendritiques sur le tonus sérotoninergique. / Growing evidence demonstrates that astrocytes could play a crucial role in the pathophysiologies of anxiety and depression as well as in the therapeutic activity of antidepressant drugs. Indeed, in vitro studies suggest that the selective serotonin reuptake inhibitors (SSRIs) stimulate the synthesis of neuroactive substances by these glial cells which are necessary for the proliferation and maturation of neuronal progenitors but also for the maintenance of the neuronal survival. Brain-derived neurotrophic factor (BDNF) is one of these substances, but its cellular origin has yet to be demonstrated in embedded systems such as living animals. In this context, the first part of this thesis was aimed at clarifying whether astrocytes constitute a source of BDNF in response to the chronic administration of the SSRI, fluoxetine, in both naive and anxio-depressive mice exposed to corticosterone (" CORT" model). In this prospect, we used a novel and efficient gene transfer strategy inducing BDNF overexpression specifically in the astrocytes of the hippocampus. Our results indicated that BDNF overexpression produced anxiolytic-/antidepressant-like activity in the novelty suppressed feeding paradigm in relation with the stimulation of hippocampal neurogenesis in naive mice but not in the CORT model. We also showed that BDNF could act on astrocytes themselves (autocrine mechanism) to improve the hippocampal astrocytic network but also on the pre-synaptic serotonergic nerve terminals (paracrine mechanism) to limit the local serotonin release. Different arguments from the literature suggest that the latter mechanism may be favorable to an anxiolytic-like activity of fluoxetine. Given that astrocytes express at the surface a variety of serotonin receptors, we then raised the possibility that the 5-HT2A receptor subtype may be a key element in the synthesis and/or release of BDNF and thereby modulating the vulnerability to depression and/or the response of fluoxetine. In the second part of this thesis, a genetic approach with mutant mice constitutively lacking the 5-HT2A receptor (5-HT2A-/-) was applied. In contrast to Lenti-BDNF mice, we showed that 5-HT2A-/- mice were more prone to develop anxio-depressive-like symptoms in response to the chronic exposure to corticosterone. Moreover, these mutants were resistant to the chronic administration of fluoxetine compared to 5-HT2A+/+ wild type mice. In order to clarify the mechanism underpinning these observations, we demonstrated that the inactivation of the 5-HT2A receptor was associated with a hypersensitivity of a negative feedback exerted by the somatodendritic 5-HT1A autoreceptors on serotonergic tone.Together these data suggest that astrocytes act in concert with neurons to regulate mood and antidepressant drug response, notably through the synthesis and/or release of BDNF following the activation of the 5-HT2A receptor. More generally, our results illustrate the concept of the tripartite synapse in which the bidirectional communication between astrocytes and monoaminergic neurons would be essential in the regulation of higher brain functions.